Literature DB >> 1489201

Penetration of vancomycin in uninfected sternal bone.

L Massias1, C Dubois, P de Lentdecker, O Brodaty, M Fischler, R Farinotti.   

Abstract

Concentrations of vancomycin in sternal bones of 10 patients undergoing cardiac surgery were studied at steady state, 48 h after starting intravenous prophylaxis. A sample of sternal bone was taken before (group I) or after (group II) cardiopulmonary bypass. The mean vancomycin concentrations in sternal bones were not significantly different between the groups and were 9.3 +/- 3.0 micrograms/g. The concentrations of vancomycin in sternal bones were always above the MICs for staphylococci, streptococci, and enterococci.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1489201      PMCID: PMC284370          DOI: 10.1128/AAC.36.11.2539

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Determination of bone and fat concentrations following systemic cefamandole and regional cefuroxime administration in patients undergoing knee arthroplasty.

Authors:  C Hoddinott; A M Lovering; H C Fernando; J H Dixon; D S Reeves
Journal:  J Antimicrob Chemother       Date:  1990-12       Impact factor: 5.790

2.  Antibiotic-tolerant Staphylococcus aureus.

Authors:  C Watanakunakorn
Journal:  J Antimicrob Chemother       Date:  1978-11       Impact factor: 5.790

3.  Vancomycin concentrations in infected and noninfected human bone.

Authors:  A L Graziani; L A Lawson; G A Gibson; M A Steinberg; R R MacGregor
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

4.  [Penetration of cefazolin into bone].

Authors:  C Quentin; P Cantet; M C Saux; A Aran; A Le Rebeller; C Bebear
Journal:  Therapie       Date:  1985 Mar-Apr       Impact factor: 2.070

5.  Cefamandole bone diffusion in patients undergoing total hip replacement.

Authors:  A J Roncoroni; C Manuel; C Nedjar; J Bauchet; D Mariani
Journal:  Chemotherapy       Date:  1981       Impact factor: 2.544

6.  Concentrations of vancomycin in bone and serum of normal rabbits and those with osteomyelitis.

Authors:  K J Wilson; J T Mader
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

7.  Vancomycin blood levels during cardiac bypass surgery.

Authors:  T W Austin; J Leake; J C Coles; M M Goldbach
Journal:  Can J Surg       Date:  1981-07       Impact factor: 2.089

8.  Vancomycin prophylaxis in cardiac operations: determination of an optimal dosage regimen.

Authors:  B F Farber; A W Karchmer; M J Buckley; R C Moellering
Journal:  J Thorac Cardiovasc Surg       Date:  1983-06       Impact factor: 5.209

9.  Effect of cardiopulmonary bypass on vancomycin and netilmicin disposition.

Authors:  K J Klamerus; K A Rodvold; N A Silverman; S Levitsky
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

10.  Distribution of sodium cefazolin in serum, muscle, bone marrow, and bone of normal rabbits.

Authors:  D H Pitkin; C Sachs; I Zajac; P Actor
Journal:  Antimicrob Agents Chemother       Date:  1977-04       Impact factor: 5.191

View more
  14 in total

1.  Prospective Cohort Study of the Tolerability of Prosthetic Joint Infection Empirical Antimicrobial Therapy.

Authors:  Claire Triffault-Fillit; Florent Valour; Ronan Guillo; Michel Tod; Sylvain Goutelle; Sébastien Lustig; Michel-Henry Fessy; Christian Chidiac; Tristan Ferry
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

2.  Extended-duration dosing and distribution of dalbavancin into bone and articular tissue.

Authors:  Michael W Dunne; Sailaja Puttagunta; Craig R Sprenger; Chris Rubino; Scott Van Wart; James Baldassarre
Journal:  Antimicrob Agents Chemother       Date:  2015-01-05       Impact factor: 5.191

3.  Vancomycin Serum Concentration Monitoring : The Middle Ground is Best.

Authors:  F Marra; B Cairns; P Jewesson
Journal:  Clin Drug Investig       Date:  1996-08       Impact factor: 2.859

4.  Vancomycin pharmacokinetic and pharmacodynamic models for critically ill patients with post-sternotomy mediastinitis.

Authors:  Olivier Mangin; Saïk Urien; Jean-Luc Mainardi; Jean-Yves Fagon; Christophe Faisy
Journal:  Clin Pharmacokinet       Date:  2014-09       Impact factor: 6.447

Review 5.  Systemic antibiotic therapy for chronic osteomyelitis in adults.

Authors:  Brad Spellberg; Benjamin A Lipsky
Journal:  Clin Infect Dis       Date:  2011-12-12       Impact factor: 9.079

6.  Penetration of vancomycin into mediastinal and cardiac tissues in humans.

Authors:  C Martin; M Alaya; M N Mallet; X Viviand; K Ennabli; R Said; P De Micco
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

Review 7.  Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations.

Authors:  Cornelia B Landersdorfer; Jürgen B Bulitta; Martina Kinzig; Ulrike Holzgrabe; Fritz Sörgel
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 8.  Lipid-based nanosystems for targeting bone implant-associated infections: current approaches and future endeavors.

Authors:  Magda Ferreira; Sandra Aguiar; Ana Bettencourt; Maria Manuela Gaspar
Journal:  Drug Deliv Transl Res       Date:  2021-02       Impact factor: 4.617

9.  Novel Bone-Targeting Agent for Enhanced Delivery of Vancomycin to Bone.

Authors:  Zaineb A F Albayati; Manjula Sunkara; Suzannah M Schmidt-Malan; Melissa J Karau; Andrew J Morris; James M Steckelberg; Robin Patel; Philip J Breen; Mark S Smeltzer; K Grant Taylor; Kevyn E Merten; William M Pierce; Peter A Crooks
Journal:  Antimicrob Agents Chemother       Date:  2015-12-14       Impact factor: 5.191

10.  Glycopeptide bone penetration in patients with septic pseudoarthrosis of the tibia.

Authors:  Silvia Garazzino; Alessandro Aprato; Lorena Baietto; Antonio D'Avolio; Agostino Maiello; Francesco Giuseppe De Rosa; Domenico Aloj; Marco Siccardi; Antonio Biasibetti; Alessandro Massè; Giovanni Di Perri
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.